FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?

被引：3
|
作者：
Gill, U. S. [1 ]
Al-Shamma, S. [1 ]
Burke, K. [1 ]
Ross, V. [1 ]
Kooner, P. [1 ]
Marley, R. [1 ]
Foster, G. R. [1 ]
Kennedy, P. T. F. [1 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, London, England
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60715-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
713
引用
收藏
页码：S286 / S286
页数：1
相关论文
共 50 条
  • [1] FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?
    Gill, U. S.
    Al-Shamma, S.
    Burke, K.
    Ross, V.
    Marley, R.
    Kooner, P.
    Foster, G. R.
    Kennedy, P. T. F.
    GUT, 2011, 60
  • [2] Tenofovir Disoproxil Fumarate In Chronic Hepatitis B
    Perry, Caroline M.
    Simpson, Dene
    DRUGS, 2009, 69 (16) : 2245 - 2256
  • [3] Smaller decreases in bone mineral density in chronic hepatitis B patients receiving tenofovir alafenamide compared with tenofovir disoproxil fumarate over 96 weeks
    Fung, S.
    Chuang, W. L.
    Nishiguchi, S.
    Seto, W. K.
    Tak, W. Y.
    Erne, E. M.
    Jablkowski, M.
    Morozov, V.
    Lau, A. H.
    Suri, V.
    Flaherty, J. F.
    Kim, K.
    Gaggar, A.
    Subramanian, G. M.
    Celen, M.
    Lim, S-G
    Chan, H. L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S691 - S692
  • [4] Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B
    Tseng, Tzu-Ning
    Chen, Chien-Hung
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) : 916 - 917
  • [5] Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide
    Fong, Tse-Ling
    Lee, Brian T.
    Tien, Andy
    Chang, Mimi
    Lim, Carolina
    Ahn, Alden
    Bae, Ho S.
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (05) : 561 - 567
  • [6] Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
    Buti, Maria
    Homs, Maria
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 6 (04) : 413 - 421
  • [7] Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
    Jenh, Alice M.
    Pham, Paul A.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2010, 8 (10) : 1079 - 1092
  • [8] Evaluation of Tenofovir Disoproxil Fumarate Treatment in Patients with Chronic Hepatitis B
    Konya, Petek
    Demirturk, Nese
    INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, 2022, 4 (01): : 47 - 54
  • [9] COMPARATIVE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS
    Yu, N. Y.
    Chang, K. C.
    VALUE IN HEALTH, 2020, 23 : S532 - S532
  • [10] Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
    Lee, Dohyeong
    Yun, Byung Cheol
    Seo, Kwang Il
    Han, Byung Hoon
    Lee, Sang Uk
    Park, Eun Taek
    Lee, Jin Wook
    Jeong, Joonho
    MEDICINE, 2019, 98 (50)
12345